India’s largest microfinance institution (NBFC-MFI), CreditAccess Grameen, is recalibrating its growth strategy. While the firm saw robust recovery in FY26, Managing Director and CEO Ganesh Narayanan has signaled a deliberate move to scale down the company’s concentration on microloans in favor of a more diversified, secured retail portfolio.
Key Performance Highlights (FY26)
Despite the shift in strategy, the company demonstrated significant operational strength over the past year:
-
New Borrowers: Added approximately 1 million new clients.
-
Portfolio Growth: Expanded 14% year-on-year to reach ₹29,590 crore.
-
Market Leadership: Solidified its position as a leading NBFC-MFI, driven by strong promoter backing.
The Roadmap to 2028
The CEO outlined an ambitious vision to transform the company into a ₹50,000 crore entity by 2028. This evolution involves a structural change in their lending model:
-
Diversification into Secured Assets: The company is aggressively moving into home loans and other retail finance products to balance its risk profile.
-
Strategic Acquisitions: CreditAccess is actively scouting for acquisition opportunities in the mortgage market to accelerate the build-out of its secured business segment.
-
Retail Transformation: By 2028, the company expects a significant portion of its total assets under management (AUM) to originate from retail finance rather than traditional microfinance.
Why the Shift?
By pivoting toward secured lending, CreditAccess Grameen aims to:
-
Reduce Volatility: Microfinance is historically sensitive to regional socio-political issues and economic shocks.
-
Increase Loan Longevity: Mortgages and home loans offer longer-term relationships with customers compared to shorter microloan cycles.
-
Enhance Asset Quality: Secured lending provides collateral backing, which typically results in lower credit costs over time.
“We are looking to scale down the microfinance growth slightly to ensure we have a more balanced and sustainable portfolio through secured retail products.” — Ganesh Narayanan, MD & CEO
